Understanding Complex Product Characterization Analysis Session 2c
Exploring Complex Product Characterization Analysis Session 2c reveals several interesting facts. A presentation and panel assess analytical methods currently considered most useful and how to better develop these ...
Key Takeaways about Complex Product Characterization Analysis Session 2c
- FDA discusses additional topics in
- FDA discusses topics in
- Yiwei Li from CDER's Office of Pharmaceutical Quality shares a case study, an introduction to Iron Colloid Drug
- Deyi Zhang from the Office of Research and Standards in the Office of Generic Drugs covers Active Pharmaceutical Ingredient ...
- FDA discusses additional topics in
Detailed Analysis of Complex Product Characterization Analysis Session 2c
A presentation and panel discuss new analytical methods that are promising for generic drug development, screening, and ... A presentation and panel discuss potential gaps in Asif Rasheed from the Office of Pharmaceutical Quality discusses common issues and challenges for
Markham C. Luke from CDER's Office of Generic Drugs discusses
Stay tuned for more updates related to Complex Product Characterization Analysis Session 2c.